FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
Healthcare
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
Source: FDA Press Releases — US Government, Public Domain